Profound abnormalities in myocardial energy metabolism occur in heart failure and correlate with clinical symptoms and survival. Available comprehensive human metabolic data come from small studies, enrolling patients across heart failure causes, at different disease stages, and using different methodologies, and is often contradictory. Remaining fundamental gaps in knowledge include whether observed shifts in cardiac substrate utilization are adaptive or maladaptive, causal or an epiphenomenon of heart failure.
Introduction
Heart failure affects nearly six million people in the US. The current magnitude of this problem from a public health standpoint cannot be overstated, and the future burden on the healthcare system is likely to be increasingly significant in view of the continued high incidence of the most common risk factors such as coronary atherosclerosis, diabetes mellitus and hypertension. Current estimated direct and indirect cost of heart failure management in the US is almost 40 billion dollars per year.
The clinical hallmark of heart failure is the inability of the heart to provide adequate perfusion to the body. To serve its function as a pump, the myocardium must turn over vast amounts of adenosine triphosphate (ATP) to fuel sarcomeric contraction and relaxation, ion pumps, and macromolecular synthesis. With such high energetic requirements and an inextricable link between substrate metabolism and contractile function, it is not surprising that any compromise in the myocardium's ability to generate high-energy phosphates would be associated with heart failure.
Despite the central role of dysregulated metabolism in heart failure, there is a surprising lack of clarity with regard to the precise metabolic changes that occur in humans with this disease. Only a relatively small number of heart failure patients have been characterized in terms of myocardial substrate oxidation and uptake, each from various stages of disease, with heterogeneous causes of left-ventricular (LV) dysfunction, and with different methods of study. Not surprisingly, divergent conclusions have been drawn. The purpose of this review is to highlight current areas of controversy and agreement in substrate metabolism of the failing heart, with a particular emphasis on alterations in glucose utilization.
The failing myocardium is energy-starved
There is clear evidence that the myocardium in heart failure is energy-depleted. Myocardial ATP levels, particularly in the context of advanced heart failure, are progressively reduced by approximately 25-35% [1, 2] . Furthermore, there are substantial decreases in creatine kinase activity and total creatine pool (sum of free and phosphocreatine content) by as much as 50-70% in the failing heart [3] [4] [5] . Several lines of evidence also suggest an impaired transfer of phosphoryl groups between spatially distinct intracellular sites of ATP production and utilization in heart failure, normally occurring by means of metabolic relays (via creatine kinase, adenylate kinase, and glycolysis) that compartmentalize the ATP supply inside the cardiomyocyte without exchange with bulk cytosolic pools for improved efficiency [6] . Thus disruption of excitation-contractile function in heart failure may be more substantial than is simply suggested by measurements of bulk myocardial ATP concentrations. The altered energetic state in heart failure is complex, involving limitations in all three major ATP-synthesis pathways, namely reduced mitochondrial ATP synthesis, reduced capacity for phosphoryl transfer, and impaired glycolytic reserve.
Reversion to the fetal metabolic phenotype: still a hypothesis
The biological mechanisms leading to the abnormal myocardial energetic state in heart failure remain poorly understood. Under normal aerobic and hemodynamic load conditions, cardiac function is not limited by availability of the main energy-providing oxidizable substrates, long-chain fatty acids (FAs) and carbohydrates. However, since the profile of myocardial substrate oxidation in most models of heart failure shifts away from FA, multiple authors have drawn analogies to the metabolic behavior of the heart immediately after birth when major changes in substrate utilization also occur. In utero, when insulin levels are relatively high and oxygen tension low, glucose and lactate metabolism are the predominant source of myocardial fuel. After birth, oxygen tension and myocardial work increase, requiring a switch towards oxidation of FA. Ultimately, about 70% of the energy requirement of the adult heart under resting conditions is provided by oxidation of long-chain FAs. Myocardial glucose and FA metabolism remain tightly coupled, with increased FA metabolism inhibiting glucose metabolism and vice versa, an effect referred to as the glucose-fatty acid, or Randle cycle.
Several lines of evidence, including ultrastructural and gene expression studies, indirectly support the paradigm that in heart failure there is reversion to the fetal metabolic phenotype of preferential carbohydrate utilization at the expense of FAs. The number and size of mitochondria are decreased, and their function is impaired [7] [8] [9] [10] . Myocardial expression of genes responsible for FA oxidation is suppressed [11, 12] in concert with downregulation of key effectors of lipid metabolism and mitochondrial biogenesis, such as PPAR-a and PGC-1a [13] [14] [15] , suggesting the switch is regulated at both transcriptional and post-translational level.
A considerable body of in-vivo experimental evidence also directly supports this hypothesis of fetal phenotype switching, based on assessment of cardiac metabolic parameters using various methodologies. An early study using aortic-banded guinea pigs as a model of heart failure noted impaired palmitate oxidation coupled with significantly lower carnitine concentrations in failing myocardium compared with controls [16] . The site of this 'block' appeared to be the rate of conversion of the FA to its cognate carnitine. Notably, however, these investigators did not report any 'compensatory' increase in the rate of glucose oxidation.
Three decades later, using a canine model of pacinginduced LV dysfunction, investigators confirmed the previously observed decreased rates of FA oxidation in the failing heart [17, 18] . This drop was associated with lower activities of carnitine palmitoyl transferase-I (CPT-1) and medium-chain acyl-CoA dehydrogenase (MCAD), both key enzymes in FA metabolism. Importantly, rates of glucose uptake and oxidation were increased with heart failure, again supporting the previously proposed concept of reversion to a fetal metabolic phenotype.
Since then, these results have been borne out in humans. In a small study involving seven patients with idiopathic dilated cardiomyopathy (DCM), rates of myocardial FA uptake and oxidation measured by positron emission tomography (PET) were significantly lower compared with controls, whereas glucose uptake was increased (glucose oxidation was not measured) [19] . This shift from FA to glucose utilization was also found by directly measuring arterio-venous substrate gradients in an elegant experiment by Neglia et al. [20] . Here, 10 patients with DCM underwent cardiac catheterization with coronary sinus sampling. Baseline (and, importantly, pacinginduced stress) measurements of substrate extraction and oxidation were made following infusions of radiolabeled substrates. Rates of FA uptake and oxidation were convincingly lower and glucose uptake increased in the heart failure group compared with controls (although, again, glucose oxidation was not directly measured).
The concept that heart failure promotes a fetal pattern of substrate utilization is widely discussed [21, 22 ] . Given the very small clinical studies to date and the limitations in measuring substrate oxidation in humans, little is known about the extent to which different metabolic pathways are deregulated in patients with various forms of heart failure. Moreover, it remains unclear whether this shift away from FA oxidation is a late consequence of heart failure, an adaptive response associated with the overall fetal molecular phenotype, or even causal in the progression of heart failure. Addressing these issues is of fundamental importance for the design of stage-specific metabolic interventions aimed to restore myocardial substrate oxidation in heart failure patients.
Alternative substrate-utilization paradigms
It is important to recognize that depressed FA oxidation has not been observed in every study of heart failure. In fact, the first study to examine substrate preference of the failing heart in humans by indirect calorimetry documented significant increases in FA uptake and utilization in heart failure patients compared with controls [23] . Conversely, glucose metabolism was found to be suppressed. Of note, the study was small and enrolled heart failure patients across nonischemic causes.
Several subsequent PET studies supported these observations. Using [ 18 F]-FDG and the FA tracer [ 18 F]-fluoro-6-thia-heptadecanoic acid, Taylor et al. [24] reported lower glucose and higher FA uptake among 12 patients with New York Heart Association (NYHA) class III heart failure compared to historical controls (the study lacked matched controls). This group then went on to show that following 3 months of treatment with the mixed a and b-blocker carvedilol, FA use by PET was significantly decreased, whereas glucose remained unchanged (but trended up) [25] . The authors noted a significant increase in ejection fraction (26 AE 2% to 37 AE 4%) associated with carvedilol therapy and the fall in FA utilization, a finding that would seemingly argue against the idea of impaired FA oxidation in heart failure. Indeed, previous studies have also found that b-blockers increase myocardial energetics and function by enhancing glucose oxidation at the expense of FAs [26] [27] [28] . Another study found no significant difference in myocardial glucose uptake by PET among clinically stable heart failure patients compared with age-matched controls [29] . Oxidative metabolism was increased in the right but not the left ventricle, suggesting a metabolic imbalance between the ventricles in the failing heart. Consistent with the above PET studies, direct quantification of myocardial metabolic substrate uptake by the arterio-venous gradient technique combined with a systemic infusion of 2 H 2 -palmitate revealed no differences between patients with compensated heart failure, type-2 diabetes, and matched controls [30 ] . Although limited by inclusion of patients with both idiopathic and ischemic heart failure causes, lack of coronary blood flow and substrate oxidation measurements, this study suggested that the human moderately failing heart is not clearly prone to increased glucose utilization.
Most recently, we reported transcoronary gradients of substrate extraction among 37 patients undergoing cardiac surgery [31 ] . Neither glucose nor FA extraction was significantly different between patients with or without LV dysfunction at baseline. Although rates of substrate oxidation were not measured directly, transcoronary elution of acylcarnitines -metabolic intermediates reflective of FA, amino acid and glycolytic metabolismwere not different based on the presence or absence of LV dysfunction. Once again, there was no clear signal in humans to support the hypothesis of reversion to a fetal pattern of metabolism in heart failure.
The roles of hyperadrenergic state and insulin resistance in metabolic abnormalities in heart failure Opie [32] proposed an intriguing concept that the hyperadrenergic state of heart failure initiates an adverse metabolic vicious cycle, whereby aberrant metabolism and in some cases insulin resistance further promote the progression of heart failure. Briefly, the compensatory sympathetic activation invoked by heart failure results in the following parallel chains of events: increased circulating FA -reduced glycolysis and glucose uptake (by heart and skeletal muscle) -increased plasma glucoseincreased reactive oxygen species -reduced glycolysis (glyceraldehyde-3-phosphate dehydrogenase) -multifactorial insulin resistance; increased circulating FAincreased FA uptake -FA activation and mitochondrial transport (CPT-1) -uncoupled mitochondrial respiration and oxygen waste [33] .
Increasing epidemiological evidence suggests a bidirectional relationship between insulin resistance and heart failure. A robust association exists between type 2 diabetes, insulin resistance, and increased incidence of heart failure, whereas diabetic cardiomyopathy has become a diagnostic entity with recognized myocardial metabolic alterations supporting a possible causative link. Conversely, preliminary evidence also suggests that heart failure may predispose to insulin resistance and type 2 diabetes. Early hyperinsulinemic-euglycemic clamp studies reported that, irrespective of cause, heart failure is associated with systemic insulin resistance that independently predicts increased mortality [34] . However, it has since been proposed that although whole body and myocardial insulin resistance do not invariably coexist and may have different pathophysiologic mechanisms, heart failure is associated with the development of myocardial insulin resistance. This concept is based on several lines of evidence. First, a number of PET studies suggest that failing human myocardium has reduced glucose uptake in favor of FA uptake [23, 24] , irrespective of diabetic status or ischemic versus nonischemic cause of heart failure [35] . Two recent elegant experimental studies in rat models of pressure overload [36] and postinfarct-induced heart failure [37 ] have reported the development of myocardial insulin resistance associated with substantial reductions in both FA and glucose oxidation. In the case of pressure overload heart failure, cardiac insulin resistance preceded the onset of mitochondrial and contractile dysfunction [36] , suggesting a potential causal link. This is consistent with data in genetically engineered mice with impaired myocardial insulin signaling by cardiomyocyte-selective ablation of the insulin receptor, which led to mitochondrial dysfunction through co-ordinated reductions in tricarboxylic acid and FA oxidative capacity, as well as oxidative stress and mitochondrial uncoupling [38 ] . Finally, indirect evidence is provided by preliminary studies of the incretin hormone glucagonlike peptide 1, known to increase plasma insulin levels and mitigate insulin resistance, which was shown to ameliorate heart failure [39] .
The complex interaction between myocardial substrate metabolism, degree of contractile dysfunction, insulin resistance, and b-blocker medication has been recently addressed in both clinical and experimental studies. Tuunanen et al. [40] made the intriguing observation that, although myocardial substrate metabolism (by PET) in DCM patients is generally shifted from FA utilization towards alternative substrates, this shift is modulated and counteracted by further deterioration of LV function and development of insulin resistance.
The metabolic effects of b-blockers are to decrease myocardial FA uptake and improve work efficiency. Most studies have shown that b-blockers increase whole body insulin sensitivity in patients with heart failure. In the heart, a shift towards increased glucose metabolism in patients with heart failure has been reported with nonselective b-blockers but not with b1-specific blockers [25, 41] .
Myocardial utilization of the main metabolic substrates glucose and long-chain FA is regulated not only by substrate availability and competition at the level of the mitochondria, but also at the site of cellular entry. Both experimental and human data have shown that shifts in myocardial fuel balance associated with heart failure can be linked to altered regulation of sarcolemmal substrate transporters, which we briefly review below. In the case of glucose metabolism, deregulation of both facilitated-diffusion glucose transporters (GLUT1 and GLUT4) and sodium-dependent glucose transporter (SGLT1) has been demonstrated in heart failure. Overall downregulation of myocardial GLUT expression is accompanied by an increase in GLUT4/GLUT1 ratio in heart failure [12] , without significant differences between diabetic and nondiabetic patients [42 ] . Conversely, myocardial SGLT1 is upregulated in end-stage diabetic and ischemic cardiomyopathy, but not changed in DCM. Furthermore, SGLT1 expression was increased following implantation of a LV assist device, and correlated with functional recovery, suggesting that upregulation of SGLT1 may be an adaptive response to injury [43 ] . One functional role of glucose transporters in human myocardium is to mediate the substrate-dependent positive inotropic effects of insulin, which has been demonstrated to occur in both normal and failing (ischemic > nonischemic) human hearts via the glucose transporters GLUT4 and SGLT1 [44 ] . Additional insight is provided from genetically engineered GLUT4 knockout mice, which surprisingly displayed cardiac hypertrophy [45] associated with a compensatory upregulation of GLUT1 and downregulation of proteins required in FA utilization [46] . Increasing insulin-independent glucose uptake and glycolysis in adult hearts by cardiac-specific overexpression of GLUT1 in mice not only did not compromise cardiac function but protected against progression to heart failure and improved survival after chronic pressure overload, seemingly because of the higher efficiency of glucose compared with FA utilization with respect to oxygen consumption [47] . However, a follow-up study using the same transgenic mouse model of cardiac-specific GLUT1 overexpression showed that, whereas complete adaptation to chronic increases in glucose uptake and oxidation occurred, failure to upregulate myocardial FA oxidation during high fat dietinduced obesity resulted in increased oxidative stress, FA overload and contractile dysfunction. The authors conclude that chronic changes in substrate availability induce adjustments in cardiac metabolic networks at the expense of network flexibility, thus rendering it vulnerable to accelerated deterioration when other stressors superimpose [48 ] .
On the contrary, the concept that both glucose and FA oxidation are required for optimal function of the failing heart is supported by clinical studies of acute FA deprivation by acipimox, an inhibitor of lipolysis, that unexpectedly resulted in further depression of cardiac work, uncoupling of cardiac contractile function from oxidative metabolism, and reduced cardiac efficiency in DCM heart failure patients in contrast to healthy controls [49] . The importance of these results is two-fold. Mechanistically, it suggests that myocardial FA oxidation enzymes can be acutely upregulated in patients with moderately severe heart failure when FA levels are suppressed. Therapeutically, it argues against the prevalent current paradigm that acutely switching myocardial substrate metabolism from FA to glucose may be beneficial for the failing heart, at least when secondary to DCM; however, these conclusions cannot be generalized to long-term metabolic modulation.
The complexity of myocardial substrate utilization in heart failure is also indirectly suggested by several studies demonstrating a 'reverse epidemiology' of obesity and hyperglycemia in the prognosis of patients with chronic, established heart failure. Higher body mass index (BMI), high HbA 1c [50, 51 ] , and higher levels of fasting glycemia [52 ] have been unexpectedly associated with improved rather than impaired outcomes in chronic heart failure, irrespective of diabetic status. Though not directly tested, availability of glucose as the preferred fuel for the failing heart with compromised energetic state has been speculated as a possible explanation for these paradoxical findings.
As a corollary to the studies presented above, Taegtmeyer and Ballal [53] proposed the concept that metabolic extremes, either as fuel overabundance or absence, can cause lipotoxicity or glucotoxicity, both of which are adverse for the failing heart and lead to contractile dysfunction.
Reconciling the discrepancies
The currently available data on substrate preferences in heart failure stem from small studies enrolling patients across heart failure causes, with different clinical staging and metabolic backgrounds, and importantly using different technologies. This makes reconciliation of these disparate findings difficult. However, insights provided by recent studies in animal models provide some useful clues.
Chandler et al. [54] created an experimental model of permanent LV dysfunction -in contrast to reversible heart failure models induced by rapid pacing -by embolizing microparticles to the coronary arteries in dogs. These hearts demonstrated significant functional impairment as measured by rate-pressure product, dP/dt, and LV ejection fraction (LVEF) (28 AE 1%), but the animals were otherwise considered to be well compensated and their heart failure characterized as 'moderate'. Under these conditions, FA uptake and oxidation was higher and glucose utilization was lower than in control animals, again seemingly at odds with the hypothesis of reversion to a fetal metabolic phenotype. The authors speculated that myocardial glucose metabolism may only be enhanced in late stages of heart failure.
A subsequent study of ischemic cardiomyopathy in mice demonstrated that whereas genes involved in the metabolism of both glucose and FA were initially downregulated for the first month after myocardial infarction, by 3 months levels of these transcripts had essentially normalized in the surviving myocardium [55] . These changes were accompanied by activation of other markers of the fetal gene program (e.g. ANF and b-MHC induction). These results suggest that although dysregulated in the acute phase, during the more stable, chronic phase of heart failure, there may be gradual normalization of metabolic control.
In follow-up to their group's previous reports of tachypacing-induced heart failure [17, 18] , Qanud et al. [56] recently reported that substrate switching towards enhanced glucose metabolism during severe heart failure was reversible in the recovery phase following cessation of pacing. Although largely normalized towards baseline, the recovering ventricles still demonstrated some functional impairment, including depressed LVEF and dP/dt max . The authors concluded that cardiac substrate selection returns to normal during postheart failure recovery, but an additional interpretation, consistent with Chandler et al. [54] is that milder forms of compensated LV dysfunction are not associated with significant changes in myocardial substrate preferences.
Most recently, using a rat model of chronic pressure overload-induced hypertrophy and transition to heart failure, Doenst et al. [57 ] sequentially quantified myocardial FA and glucose oxidation ex vivo during the development of heart failure and contractile dysfunction. They found an early impairment of FA oxidation (at 2 weeks) preceding the onset of heart failure in vivo, which was associated with a progressive decrease in glucose oxidation. In contrast, mitochondrial respiratory capacity was maintained in the early stages of heart failure (with preserved LVEF), and declined only later (after 10 weeks) in hearts with contractile dysfunction. Interestingly, although the observed increased ratios of glucose to FA oxidation in heart failure could be interpreted as a shift towards greater reliance on glucose utilization, in fact both oxidation rates decreased and the 'shift' only reflected a greater relative reduction in FA oxidation. Using the same rat model of chronic pressure overload this group has further reported that development of mitochondrial dysfunction, which appears specific to the interfibrillar mitochondria, may outweigh the benefits of preferential glucose oxidation by limiting overall oxidative capacity in the heart, and contribute to cardiac decompensation in late-stage heart failure [58 ] .
Hence, a potential unifying notion to explain the disparate data of cardiac substrate selectivity in humans with heart failure would be that in the early phases of the disease, there is an increase in FA metabolism (due to increased availability), which inhibits myocardial glucose metabolism but ultimately overloads the system and results in accumulation of FA intermediates and negative feedback inhibition of FA oxidation via malonyl CoA and CPT-1. This perpetual metabolic inefficiency leads first to loss of energy reserve supported by creatine kinase, with a reduction in phosphocreatine levels. In advanced heart failure, FA metabolism is significantly reduced, driven in principal by downregulation of PPAR-a as the heart suppresses adult metabolic gene transcripts and reverts to a fetal phenotype, in parallel with an increase in glycolysis uncoupled from glucose oxidation. This metabolic remodeling, mirroring that seen in hibernating myocardium [59, 60] , then becomes a prosurvival adaptation for the cardiomyocyte in response to stress [21] . However, further depression of LV function and development of profound insulin resistance induce a shift back to greater FA uptake and oxidation, which appears to be independent of b-blocker medication [40] . Ultimately, impaired mitochondrial oxidative capacity and metabolic inflexibility result in catastrophic energy failure with reductions in both ATP and phosphocreatine. These alterations in mitochondrial function and biogenesis in end-stage heart failure are caused by reduced expression of the metabolic master regulator PGC-1a, and are at least in part mediated via endothelin-1 and angiotensin II [61 ] .
Although no study to date has enrolled sufficient patients in detailed metabolic analyses to adequately stratify by disease duration or NYHA class, reasonable evidence exists that different pathways for ATP synthesis are compromised at different times and to different extents in the progression of heart failure, and therefore interventions designed to alter metabolic pathways must be matched to the stage of metabolic deregulation, analogous to NYHA classes.
The dysfunctional heart lacks metabolic flexibility
In recent years, a striking picture has begun to emerge that the failing heart, which clearly lacks mechanical reserve, also lacks the metabolic and energetic reserve to deal with hemodynamic stress. Qanud et al. [56] demonstrated that in response to rapid pacing, the failing canine heart was unable to significantly increase its oxidation of FA or glucose, as was the normal myocardium. Importantly, even in those hearts which had been allowed to recover to near-normal function following tachycardia-induced pacing and which appeared metabolically identical to control hearts at baseline, the initiation of rapid pacing led to significant drops in FA oxidation and the inability to increase myocardial oxygen consumption.
The contention that the failing heart lacks metabolic flexibility to deal with stress has been shown in humans, as well. In their study of patients with nonischemic cardiomyopathy, Neglia et al. [20] found the dysfunctional ventricles unable to augment their substrate uptake or oxidation in response to pacing stress. The result was mechanical inefficiency and an inability to increase the indexed rate-pressure product compared with normal controls.
Although no significant differences in baseline substrate utilization were seen between patients with and without heart failure, in the study by Turer et al. [31 ] marked changes in substrate uptake were noted among those with LV dysfunction following global myocardial ischemiareperfusion associated with surgical cardioplegic arrest. Under these conditions, fuel uptake was massively deranged, and the myocardium appeared to favor anaerobic metabolism. 'Unmasking' of this underlying metabolic fragility by the ischemic stress was associated with increased duration of inotropic support, again highlighting the relationship between hemodynamic decompensation and perturbed cardiac metabolism.
Overall, it appears that the dysfunctional ventricle, which undergoes chronic modulation to alter its substrate selection, nonetheless remains at a precarious equilibrium. Underlying metabolic derangements become manifest under stress conditions (e.g. ischemia or high workloads). Whether a direct cause of the resulting hemodynamic effects or just an association is unclear, but it is intriguing to speculate that acute metabolic shifts may be a key inciting mechanism of heart failure flares. Indeed, recent transgenic murine models of pyruvate dehydrogenase inhibition [62] and phosphocreatine deficiency [63], which at baseline display no obvious myocardial phenotype, undergo cardiac decompensation with stress.
Conclusion
Excitation-contraction-relaxation coupling in the heart is critically dependent on a continuous supply of highenergy phosphates. Since the myocardial energetic state is clearly altered in the setting of heart failure, it is reasonable to suggest that it may also play a role in the progression of disease. However, the processes involved in disruption of ATP synthesis, the timing and consequences of switches in substrate utilization, and the potential reversibility of energetic defects in heart failure remain incompletely characterized. Discrepancies in the published clinical and experimental data likely reflect the heterogeneity of study design and patient characteristics, as well as methodological difficulties of measuring metabolic fluxes in intact tissues. These prominent gaps in our knowledge present hurdles to our ability to modulate metabolism of the failing heart.
Heart failure is a public health problem with enormous financial and human tolls. With risk factors continuing to increase in prevalence worldwide, heart failure prevalence will also continue to rise. Our current level of understanding of alterations in cardiac metabolism remains inadequate given the scope of this disease. Our goals should be to more clearly understand how perturbations in cardiac metabolism may be related to the pathophysiology of heart failure and importantly how metabolism may be modulated to maximize the efficiency of existing myocardium. This will require larger studies enrolling patients with different causes and stages of disease progression.
